How will knowledge of the human genome affect drug therapy

British Journal of Clinical Pharmacology

Volumn 47, Issue 1, 1999, Pages 7-10

  Grahame Smith, D G ^a  

^a RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOME; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; SHORT SURVEY;

GENE EXPRESSION; GENOME, HUMAN; HUMANS; MOLECULAR BIOLOGY; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY, CLINICAL;

EID: 0032954779     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00909.x     Document Type: Short Survey

References (5)

1. 1 Southern EM. DNA chips: analysing sequence by hybridizing to oligonucleotides on a large scale. Trends in Genetics 1996; 12: 110-115.
2. 2 Weber WW. Pharmacogenetics, Oxford University Press, Oxford. 1997.
3. 3 Grahame-Smith DG. The Lilly Prize Lecture. 'Keep on taking the tablets': pharmacological adaptation during long-term drug therapy. Br J Clin Pharmacol 1997; 44: 227-238.
4. 4 Medical Research Council. MRC trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-412.
5. 5 Kuivenhoven JA, Jukema W, Zwinderman AH, et al. The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.